Additional Subscription

GENinCode (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer, is pleased to announce that further to the Fundraising initially announced on 21 January 2026, it has received addition interest from investors.

The board consider that it would be materially beneficial to the Company and shareholders to have the additional funding and secure a longer cash runway for the business as it works to provide the FDA with the necessary updates for its De Novo application for its CARDIO inCode-Score test.

It has therefore agreed to an additional element of the Fundraise to include a subscription (the "Additional Subscription") for a further 58,000,000 New Ordinary Shares at the Issue Price of 1 pence per share ("Additional Subscription Shares"), raising further gross proceeds of £580,000. The terms of the Additional Subscription are materially the same as those in the Fundraising, including price, conditions and admission, which will be on 11 February 2026. While the demand was materially greater than this level, the Company was limited by its authorities, with the Additional Subscription Shares being issued using the additional authority set out in the Resolutions proposed at the General Meeting and the authority granted to the directors at the annual general meeting of the Company on 30 June 2025.

Accordingly, conditional on the passing of the Resolutions at the General Meeting, the Company has raised total gross proceeds of approximately £4.7 million in aggregate by way of the Fundraising.

Terms used but not defined in this announcement have the same meaning as set out in the Company's announcement released on 21 January 2026 save that the definition of Fundraise shall include the Additional Subscription.

Further information on the Company can be found on its website at https://investors.genincode.com

The Company's LEI is 213800UX6TE7K65O2892.